The difference between A549 NSCLC cells and malignant mesothelioma REN and EMMESO cells regarding HMGB1 secretion (Figure 2A) suggests that different cancer cells will differ in their capacity to secrete HMGB1 in response to cisplatin therapy. Here, HMGB1 is linked to malignant mesothelioma.